Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
–Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality cont...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ: CAPR) with a Buy and maintains $2...
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its r...
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $24...
- SEC Filing
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stoc...
